Home > Press > Arrowhead to Present at 10th Annual Meeting of the Oligonucleotide Therapeutics Society
 |
Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company is presenting at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society being held on October 12-15, 2014 in San Diego. Scheduled conference presentations include the following:
Arrowhead to Present at 10th Annual Meeting of the Oligonucleotide Therapeutics Society
Pasadena, CA | Posted on October 7th, 2014October 12, 2014 - A poster presentation titled, "Kinetics of DPC-mediated delivery of cholesterol-conjugated RNAi triggers and their subcellular processing in vivo," will be presented by Christine Woodell, Ph.D., Group Leader
October 15, 2014 - An oral presentation titled, "Development of RNAi-based therapeutics using Dynamic Polyconjugate (DPC) delivery technology," will be presented by David Lewis, Ph.D., Chief Scientific Officer
####
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.
For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit ir.arrowheadresearch.com/alerts.cfm.
For more information, please click here
Contacts:
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
or
Investor Relations:
The Trout Group
Lauren Glaser
646-378-2972
or
Media:
Russo Partners
Martina Schwarzkopf, Ph.D.
212-845-4292
Copyright © Arrowhead Research Corporation
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
| Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||